Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · USD

$10.5

-0.01 (-0.1%)· Recorded snapshot

Market cap	885.8M
Net income (ttm)	-54.1M
EPS (ttm)	-$0.62
Shares out	84.1M
Volume	753,569
Beta	1.43

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -54.1M
EPS (ttm): -$0.62
Market cap: 885.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-35.4

P25 n/aP50 n/aP75 n/a

ROIC-23.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CRVS indicators

Market & fundamental data

Available fields

181

Groups with data

Currency

USD

Showing 181 of 181 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001626971
Company name	Corvus Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	221015100
Earnings date	2026-11-10
Earnings time	amc
Employees	37
Employees change	6
Employees growth	19.35%
Enterprise value	$671.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2016-03-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US2210151005
Last 10-K release date	2026-03-12
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$885.8M
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$10.53
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CRVS
U.S. state	California
Website	https://www.corvuspharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-5.93%
FCF / EV yield	-6.83%
FCF yield	-5.16%
P/B ratio	3.93x
Price / tangible book value	3.89x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.5M
ROA	-21.66%
ROA (5Y)	-28.24%
ROCE	-25.25%
ROE	-35.43%
ROE (5Y)	-73.89%
ROIC	-23.17%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-698,000
Depreciation and amortization	$117,000
EBIT	$-57M
EBITDA	$-56.8M
EPS	$-0.62
FCF per share	$-0.54
Financing cash flow	$191.3M
Free cash flow	$-45.2M
Free cash flow minus SBC	$-53.3M
Investing cash flow	$-142.5M
Net cash flow	$4.2M
Net income	$-54.1M
Operating cash flow minus SBC	$-52.6M
Operating income	$-57M
Stock-based compensation	$8.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.68
Debt / equity	0
Long-term assets	$18.3M
Long-term liabilities	$274,000
Net cash (debt)	$214.5M
Net cash / market cap	24.47%
Net cash growth	192.54%
Net debt / equity	-0.95
Piotroski F-Score	2
Property, plant and equipment	$1.5M
Shareholders' equity	$225.3M
Tangible book value	$225.3M
Tangible book value per share	$2.68
Total assets	$239.3M
Total cash	$215.2M
Total debt	$728,000
Total liabilities	$13.9M
WACC	12.12%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$221M
Current liabilities	$13.7M
Current ratio	16.16
Net working capital	$-7.5M
Quick ratio	15.88
Working capital	$207.3M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-22.16%
Dividend yield	0%
Shareholder yield	-22.16%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-23.58%
10Y return CAGR	-2.65%
10Y total return	-23.58%
150-day SMA	$13.42
1D price change	-0.09%
1M price change	-9.38%
1M total return	-9.38%
1W price change	4.78%
1W total return	4.78%
1Y price change	33.97%
1Y return CAGR	34%
1Y total return	33.97%
20-day SMA	$10.26
200-day SMA	$14.41
3M price change	-18.5%
3M total return	-18.5%
3Y price change	840.18%
3Y return CAGR	111.02%
3Y total return	840.18%
50-day SMA	$12.13
50-day SMA vs 200-day SMA	50under200
52-week high	$26.95
52-week high date	2026-01-23
52-week low	$6.39
52-week low date	2026-01-12
5Y price change	130.92%
5Y return CAGR	18.22%
5Y total return	130.92%
6M price change	-33.86%
6M total return	-33.86%
All-time high	$26.95
All-time high date	2026-01-23
All-time low	$0.61
All-time low date	2023-03-28
Average true range (ATR)	$0.60
Average volume	1.1M
Beta (1Y)	0.82
Beta (2Y)	0.99
Beta (5Y)	1.43
Change from 52-week high	-60.93%
Change from 52-week low	64.79%
Change from all-time high	-60.93%
Change from all-time low	1,634.76%
Change from open	1.54%
Day's gap	-1.61%
Dollar volume	$7.9M
High price	$10.70
Low price	$10.31
Monthly RSI	51.79
Open price	$10.37
Position in 52-week range	56.41%
Premarket change	0.47%
Premarket close	$10.54
Premarket price	$10.59
Premarket volume	1.4K
Previous close	$10.54
Price vs 150-day SMA	-21.54%
Price vs 20-day SMA	2.67%
Price vs 200-day SMA	-26.93%
Price vs 50-day SMA	-13.2%
Relative volume	0.7
RSI	45.42
Sharpe ratio	0.64
Sharpe ratio (3Y)	1
Sharpe ratio (5Y)	0.55
Sortino ratio	2.55
Sortino ratio (3Y)	2.48
Sortino ratio (5Y)	1.18
Volume	753.6K
Weekly RSI	41.74
YTD price change	36.75%
YTD total return	36.75%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	72.8M
Float percentage	86.53%
Shares change (QoQ)	2.63%
Shares change (YoY)	22.16%
Shares held by insiders	3.54%
Shares held by institutions	76.63%
Shares outstanding	84.1M
Short % of float	24.45%
Short % of shares	21.16%
Short ratio	15.4 days

Deeper analysis on CRVS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CRVS report

Is a complete CRVS research report available?

No complete published report is available for Corvus Pharmaceuticals, Inc. (CRVS) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Corvus Pharmaceuticals, Inc. (CRVS)

Price

Financial snapshot

Fair-value bridge

Latest news · CRVS

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CRVS indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CRVS

Frequently asked questions